- secukinumab treat the immune-mediated disease by neutralizing the underlying inflammation and tissue destruction, - patients with PASI score >12 taking secukinumab, a decreased in IL-6 and CRP levels were observed after the start of treatment, - any change was seen in the PK parameters of midazolam before and after the administration of secukinumab, - PK parameters of midazolam in patients with psoriasis (study subjects) were close to those in found in healthy subjects in a previous study. Here, IL6 is linked to psoriasis.